Deere stock closes at a record after earnings pop — what could move it next week

Deere stock closes at a record after earnings pop — what could move it next week

February 22, 2026

NEW YORK, Feb 22, 2026, 12:02 EST — The market has closed.

  • Deere closed out Friday at $662.49, barely budging after its sharp move higher following earnings.
  • Lifting its 2026 profit outlook, the company pointed to solid gains from construction and equipment for smaller farms.
  • Markets head into Monday with tariffs and farm income trends still steering the outlook.

Deere & Co (DE) is set to start Monday’s session on Wall Street sitting at an all-time high, with investors piling in after the company’s new outlook and unusually strong comments on the cycle. Shares ticked up 0.07% to close Friday at $662.49.

Deere’s got weight—what happens here usually ripples out to farms, dealers, and construction outfits spending on major equipment. Its shifts tug suppliers and rivals along, good or bad.

Timing is the other factor. Trade policy’s in the mix again, rates remain a drag, and plenty of investors want more than a mere pause—they’re holding out for unmistakable signs that the machinery slump is actually letting up.

Deere’s rally actually kicked off the previous day. Shares leapt from $593.27 on Wednesday to $662.00 on Thursday, a gain of roughly 11.6%, and then edged up another 49 cents Friday, company price data show.

Deere reported net income for the first quarter dropped to $656 million, or $2.42 per share. Net sales and revenues globally moved up 13%, reaching $9.61 billion. The company lifted its net income guidance for fiscal 2026, now expecting $4.5 billion to $5.0 billion. “2026 represents the bottom of the current cycle,” CEO John May said. Deere

Analysts wasted no time sketching out the road ahead. Kristen Owen of Oppenheimer highlighted “lean inventories,” suggesting there’s some potential for gains later this year if things normalize—despite Deere estimating a roughly $1.2 billion pre-tax impact from tariffs in fiscal 2026. Reuters

Tariffs remain a headache. Stocks pushed higher Friday after the U.S. Supreme Court tossed out Donald Trump’s global tariffs, which were set under an emergency statute. Then Trump turned around and quickly rolled out a fresh 10% tariff, this time pegged for 150 days under another trade rule. For manufacturers bringing in parts or metals, that means uncertainty isn’t going away on costs—or pricing.

Another squeeze: farm cash flow. The U.S. Department of Agriculture puts 2026 net farm income—covering overall profits—at $153.4 billion, a 0.7% dip from 2025. With numbers like that, farmers may hold off on equipment upgrades, regardless of dealer incentives.

Still, this rally is vulnerable. Should tariff costs climb once more, or if crop margins remain squeezed heading into spring purchases, traders could call the stock’s move premature compared to actual demand.

The valuation piece is back in focus, too. Deere’s surge has landed it squarely in “show me” mode again—it’s not enough to post one strong quarter and lift the guidance. Sustained order flow and tighter margins will be necessary to convince fresh investors to stick around.

Friday brings January’s U.S. producer price index at 8:30 a.m. EST, a release known for shaking up bond yields and nudging financing costs for buyers of equipment. Deere shareholders are eyeing the $660 level as trading picks up again Monday, watching to see if the stock holds ground.

Marcin Frąckiewicz

Marcin Frąckiewicz is the CEO of TS2 Space and a longtime technology entrepreneur focused on telecommunications, satellite communications and digital innovation. A graduate of the Warsaw School of Economics (SGH), he writes about space technology, artificial intelligence and publicly traded technology companies. His analysis covers major market trends, emerging technologies and the businesses shaping the future of the global economy.

Stock Market Today

  • Cleo Diagnostics Moves Ovarian Cancer Test Into FDA Validation Phase, Eyes 2027 Submission
    July 27, 2026, 8:44 AM EDT. Cleo Diagnostics Limited (ASX: COV) has kicked off analytical validation for its Pre-Surgical Ovarian Cancer Test, moving closer to a FDA 510(k) clearance filing it plans by mid-2027. The Melbourne firm wrapped a pivotal trial on 514 samples from 624 women at 19 US centers. It has expanded the test to eight biomarkers and settled on Bio-Techne's Ella system for automated analysis. The current validation is aimed at checking if the test performs consistently from batch to batch, a requirement before regulatory approval. Investors are tracking Cleo's milestones as the company works toward market launch.